Clarkston Consulting
Skip to content

Clarkston Commercialization Expert Shares Guest Column on Digital CGT Strategy

January 25, 2024  |  Clarkston Consulting’s Anna Ivashko was recently featured as a guest columnist with Cell and Gene for her expertise on a digital CGT strategy. She shares perspectives on commercialization readiness for sales, marketing and operations teams at cell and gene therapy organizations. Read a short excerpt from the piece below or the full article here.

Shaping A Digitally Enabled Commercialization Road Map For Your Cell/Gene Therapy Company

“The cell and gene therapy (CGT) space is unique in its commercialization requirements. With a typical focus on rare disease, CGT organizations inherently work with small patient and key opinion leader (KOL) populations, and they often receive orphan-drug designations that expedite their approval and can lead to compressed launch readiness timelines. These factors make it critical for commercial, marketing, and digital leaders to understand key business decisions that shape the digital backbone of your commercialization road map. Focusing on CGT companies in the gene therapy and allogeneic cell therapy spaces, this article outlines some of the key questions to ask up front that will enable easier, cross-functional, and strategic decision-making … ”

Read the Full Article Here